Rhizen Pharmaceuticals SA-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Rhizen Pharmaceuticals SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014227
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Rhizen Pharmaceuticals SA (Rhizen Pharma), a subsidiary of Alembic Pharmaceuticals Ltd is a biopharmaceutical company that discovers and develops small molecule drugs. The company’s research products includes c-Met inhibitors, selective P13K inhibitors, CRAC channel inhibitors and GPR 119 agonist. It conducts research in the therapeutic areas of oncology, immune inflammation and metabolic disorders such as diabetes and obesity. Rhizen Pharma’s products find application in the treatment of diseases such as solid tumors, B cell lymphomas, hematological malignancies, asthma, diabetes and chronic obstructive pulmonary disease, among others. It collaborates with other pharmaceutical companies. Rhizen is headquartered in La Chaux-de-Fonds, Switzerland.

Rhizen Pharmaceuticals SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 11
Licensing Agreements 13
TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 13
Novartis Enters into Licensing Agreement with Rhizen Pharma 15
Rhizen Pharmaceuticals SA – Key Competitors 16
Rhizen Pharmaceuticals SA – Key Employees 17
Rhizen Pharmaceuticals SA – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Product News 19
10/13/2016: TG Therapeutics Announces the Launch of the Phase 1/2 Study of TGR-1202 and Carfilzomib in Patients with Relapsed or Refractory Lymphoma 19
06/14/2017: TG Therapeutics Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14th International Conference on Malignant Lymphoma 20
06/08/2017: TG Therapeutics Announces Clinical Data Presentation of TGR-1202 at the Upcoming 14th International Conference on Malignant Lymphoma 21
05/20/2016: TG Therapeutics Announces Clinical Data Presentations at the Upcoming 21st European Hematology Association Annual Congress 22
05/19/2017: TG Therapeutics Announces Data on TG R-1202 at the Upcoming 14th International Conference on Malignant Lymphoma 23
05/18/2016: TG Therapeutics Announces Clinical Data Presentation at the Upcoming 52nd Annual Meeting of the American Society of Clinical Oncology 24
Clinical Trials 25
Jun 13, 2017: TG Therapeutics Recaps Schedule of Clinical Data Presentations of TGR-1202 at the Upcoming 14th International Conference on Malignant Lymphoma & the 22nd European Hematology Association Annual Congress 25
Jun 05, 2017: TG Therapeutics Announces Follow-Up Data from the Chemo-Free Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 53rd Annual Meeting of the American Society of Clinical Oncology 27
Apr 20, 2017: TG Therapeutics Announces Clinical Data Presentations on TGR-1202 at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology 29
Jan 04, 2017: TG Therapeutics Announces Investigator Initiated Trial at the University of Nebraska Medical Center to Study TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma 30
Dec 06, 2016: TG Therapeutics Announces Double & Triple Combination Therapy Data Presentations at the 58th American Society of Hematology Annual Meeting 31
Dec 05, 2016: TG Therapeutics Announces Oral Data Presentation for TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL at the 58th American Society of Hematology Annual Meeting 33
Dec 05, 2016: TG Therapeutics Announces Preclinical Data Presentations for TGR-1202 at the 58th American Society of Hematology Annual Meeting 34
Dec 02, 2016: TG Therapeutics Recaps Schedule of Data Presentations at the 58th American Society of Hematology Annual Meeting 35
Oct 27, 2016: TG Therapeutics Announces Publication in Blood Describing a Novel Complimentary Mechanism of the PI3K-delta Inhibitor, TGR-1202 37
Apr 18, 2016: TG Therapeutics Announces Pre-Clinical Data Presentation on TGR-1202 Demonstrating Differentiated Effects on T-Cells 38
Mar 17, 2016: TG Therapeutics Announces Pre-Clinical Data Presentation on TGR-1202 at the 2016 American Association for Cancer Research Annual Meeting 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Key Facts 2
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rhizen Pharmaceuticals SA, Deals By Therapy Area, 2011 to YTD 2017 9
Rhizen Pharmaceuticals SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 11
TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 13
Novartis Enters into Licensing Agreement with Rhizen Pharma 15
Rhizen Pharmaceuticals SA, Key Competitors 16
Rhizen Pharmaceuticals SA, Key Employees 17

★海外企業調査レポート[Rhizen Pharmaceuticals SA-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ambac Financial Group, Inc.:企業の戦略・SWOT・財務情報
    Ambac Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ambac Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Carraro Spa:企業の戦略・SWOT・財務情報
    Carraro Spa - Strategy, SWOT and Corporate Finance Report Summary Carraro Spa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Industrial Bank Co., Ltd.:企業の戦略・SWOT・財務分析
    Industrial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Industrial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Brookfield Infrastructure Partners LP:企業のM&A・事業提携・投資動向
    Brookfield Infrastructure Partners LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Brookfield Infrastructure Partners LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed report …
  • Kwality Group
    Kwality Group - Strategy, SWOT and Corporate Finance Report Summary Kwality Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Bank of the Ryukyus, Ltd.:企業の戦略・SWOT・財務情報
    Bank of the Ryukyus, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank of the Ryukyus, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Electricite de France SA (EDF):企業の財務・戦略的SWOT分析
    Electricite de France SA (EDF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Strata Oncology Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Strata Oncology Inc (Strata Oncology) is a precision oncology company. The company offers tumor sequencing to advanced cancer patients and a portfolio of biomarker-matched precision medicine trials. It identifies patients to design and conduct transformative precision oncology trials to acce …
  • Joint Stock Company Russian Agricultural Bank:企業の戦略・SWOT・財務分析
    Joint Stock Company Russian Agricultural Bank - Strategy, SWOT and Corporate Finance Report Summary Joint Stock Company Russian Agricultural Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • Prudential Plc:戦略・SWOT・企業財務分析
    Prudential Plc - Strategy, SWOT and Corporate Finance Report Summary Prudential Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Gentera SAB de CV (GENTERA):企業の財務・戦略的SWOT分析
    Gentera SAB de CV (GENTERA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • SPAGO Nanomedical AB-医療機器分野:企業M&A・提携分析
    Summary Spago Nanomedical AB (SPAGO Nanomedical), formerly SPAGO Imaging AB is a drug company that develops proprietary magnetic resonance imaging contrast agent, and the novel therapeutic project tumorad for cancer selective radionuclide treatment. The company concentrates on research and developme …
  • Nephros Inc (NEPH):医療機器:M&Aディール及び事業提携情報
    Summary Nephros Inc (Nephros) is dialysis device manufacturer. The company offers infection control filters, dialysis ultrafilters, and hemodia filtration systems. Its dialysis ultrafilters includes Endotoxin ten Cartridge filter, SSUmini, DSU-D and SSU-D. Nephros dialysis ultrafilters are intended …
  • Shiseido Company, Limited:企業の戦略・SWOT・財務分析
    Shiseido Company, Limited - Strategy, SWOT and Corporate Finance Report Summary Shiseido Company, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • ICF International Inc (ICFI):企業の財務・戦略的SWOT分析
    ICF International Inc (ICFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • OMV AG:企業の戦略・SWOT・財務情報
    OMV AG - Strategy, SWOT and Corporate Finance Report Summary OMV AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Neuca SA (NEU):製薬・医療:M&Aディール及び事業提携情報
    Summary Neuca SA (Neuca) is a provider of pharmaceutical and medical development solutions. The company offers wholesale of pharmaceuticals and medical equipment to pharmacies and hospitals. Its services comprise private brand management, logistics and distribution, telemarketing, and education and …
  • Health Dialog Services Corp:企業の戦略的SWOT分析
    Health Dialog Services Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Datatec Limited:企業の戦略・SWOT・財務分析
    Datatec Limited - Strategy, SWOT and Corporate Finance Report Summary Datatec Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Alta Mesa Resources Inc:企業の戦略的SWOT分析
    Alta Mesa Resources Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆